for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Yield10 Bioscience Inc

YTEN.OQ

Latest Trade

0.59USD

Change

-0.02(-2.61%)

Volume

25,156

Today's Range

0.59

 - 

0.64

52 Week Range

0.59

 - 

1.76

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.61
Open
0.64
Volume
25,156
3M AVG Volume
3.53
Today's High
0.64
Today's Low
0.59
52 Week High
1.76
52 Week Low
0.59
Shares Out (MIL)
12.52
Market Cap (MIL)
7.44
Forward P/E
-0.95
Dividend (Yield %)
--

Latest Developments

More

Yield10 Bioscience Inc - Files Prospectus For Offering Of Class A Units

Yield10 Bioscience Reports Q2 Operating Loss Per Share Of $0.15

Yield10 Bioscience Q4 Operating Loss Per Share $0.19

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Yield10 Bioscience Inc

Yield10 Bioscience, Inc., formerly Metabolix, Inc., is an agricultural bioscience company. The Company is focused on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism to direct more carbon to seed production, the Company is advancing several yield traits it has developed in crops, such as Camelina, canola, soybean and corn. The Company concentrates on technologies that enables it to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter. The Company has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.

Industry

Biotechnology & Drugs

Contact Info

19 Presidential Way Ste 201

+1.617.5831700

http://www.yield10bio.com/

Executive Leadership

Robert L. Van Nostrand

Chairman of the Board, Independent Director

Oliver P. Peoples

President, Chief Executive Officer, Director

Charles B. Haaser

Chief Accounting Officer, Vice President - Finance

Lynne H. Brum

Vice President - Planning and Communications

Kristi Snell

Chief Science Officer, Vice President - Research

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-0.920

2019(E)

-0.643
Price To Earnings (TTM)
--
Price To Sales (TTM)
11.39
Price To Book (MRQ)
1.67
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
19.42
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-85.47
Return on Equity (TTM)
-74.42

Latest News

BRIEF-Yield10 Bioscience Reports Q1 Loss Per Share $0.24

* YIELD10 BIOSCIENCE ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Yield10 Bioscience Reports Q4 Loss Per Share Of $0.99

* YIELD10 BIOSCIENCE ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Yield10 Bioscience Announces Pricing Of $12.6 Mln Public Offering

* YIELD10 BIOSCIENCE ANNOUNCES PRICING OF $12.6 MILLION PUBLIC OFFERING

BRIEF-Yield10 Bioscience Grants Research License To Monsanto To Evaluate Two Novel Yield Traits In Soybean

* YIELD10 BIOSCIENCE INC - GRANTED A NON-EXCLUSIVE RESEARCH LICENSE TO MONSANTO COMPANY TO EVALUATE ITS NOVEL C3003 AND C3004 YIELD TRAITS IN SOYBEAN

BRIEF-Yield10 Bioscience posts Q3 loss $0.59/shr from continuing operations

* Yield10 Bioscience announces third quarter 2017 financial results

BRIEF-‍Yield10 Bioscience obtains confirmation of nonregulated status from USDA-APHIS for its genome-edited Camelina line​

* Yield10 bioscience obtains confirmation of nonregulated status from USDA-APHIS for its genome-edited Camelina line Source text for Eikon: Further company coverage:

BRIEF-Yield10 Bioscience Q2 loss per share $0.96 from continuing operations

* Yield10 Bioscience announces second quarter 2017 financial results

BRIEF-Yield10 Bioscience announces pricing of $2.3 mln registered direct offering

* Yield10 Bioscience announces pricing of $2.3 million registered direct offering

BRIEF-Yield10 Bioscience announces 1-for-10 reverse stock split

* Yield10 Bioscience Inc says company's common stock will begin trading on a split-adjusted basis on Tuesday, May 30, 2017 Source text for Eikon: Further company coverage:

BRIEF-Yield10 Bioscience announces Q1 revenue $300,000

* Yield10 Bioscience announces first quarter 2017 financial results

BRIEF-Yield10 Bioscience files for mixed shelf of up to $25 mln

* Files for mixed shelf of up to $25 million - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Yield10 Bioscience Q4 loss per share $0.06 from continuing operations

* Yield10 Bioscience announces fourth quarter and full year 2016 financial results

BRIEF-Yield10 Bioscience outlines plans for spring 2017 field tests of gene C3003

* Outlines plans for spring 2017 field tests of novel yield trait gene C3003 in Camelina and canola

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up